Sami Diab
- Cancer Research top 2%
- Breast Cancer Treatment Studies 11
- Cancer Genomics and Diagnostics 7
- Oncology top 1%
- Cancer Treatment and Pharmacology 14
- HER2/EGFR in Cancer Research 12
- Colorectal Cancer Treatments and Studies 11
- PARP inhibition in cancer therapy 8
-
- Advanced Breast Cancer Therapies 19
- Genetics top 5%
- BRCA gene mutations in cancer 10
Sami Diab
68 papers receiving 2.7k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Cancer Research 1.0k
- Oncology 1.8k
- Pathology and Forensic Medicine 470
- Pulmonary and Respiratory Medicine 805
- Genetics 386
Countries citing papers authored by Sami Diab
This map shows the geographic impact of Sami Diab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sami Diab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sami Diab more than expected).
Fields of papers citing papers by Sami Diab
This network shows the impact of papers produced by Sami Diab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sami Diab. The network helps show where Sami Diab may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sami Diab, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 28 | |
| 2 | 2021 | 90 | |
| 3 | Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialbreakdown → | 2020 | 252 |
| 4 | 2020 | 5 | |
| 5 | 2018 | 35 | |
| 6 | 2017 | 8 | |
| 7 | 2016 | 10 | |
| 8 | 2013 | 36 | |
| 9 | 2013 | 3 | |
| 10 | 2012 | 7 | |
| 11 | 2012 | 42 | |
| 12 | 2011 | 11 | |
| 13 | A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma | 2007 | 3 |
| 14 | 2007 | 4 | |
| 15 | 2007 | 55 | |
| 16 | 2001 | 39 | |
| 17 | Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancerbreakdown → | 2000 | 511 |
| 18 | 1999 | 8 | |
| 19 | Evidence for the duration of the antifolate action of the thymidylate synthase (TS) inhibitor ZD9331 using plasma dUrd as a surrogate marker of enzyme inhibition | 1998 | 1 |
| 20 | Plasma 2 '-deoxyuridine (dUrd) as a surrogate marker of thymidylate synthase (TS) inhibition in patients in phase I clinical trials of the TS inhibitor ZD9331 | 1998 | 1 |
About Sami Diab
Sami Diab is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Reproductive Medicine and Genetics, having authored 74 papers that have together received 2.8k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (14 papers), HER2/EGFR in Cancer Research (12 papers), Colorectal Cancer Treatments and Studies (11 papers), Breast Cancer Treatment Studies (11 papers), BRCA gene mutations in cancer (10 papers), PARP inhibition in cancer therapy (8 papers) and Cancer Genomics and Diagnostics (7 papers). The work is most often cited by research in Cancer Research (1.0k citations), Oncology (1.8k citations), Pathology and Forensic Medicine (470 citations), Pulmonary and Respiratory Medicine (805 citations) and Genetics (386 citations). Sami Diab has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Richard Elledge, Gary M. Clark, D. Ross Camidge, C. Kent Osborne, Lia Gore, D. Craig Allred, Cindy L. O’Bryant, Laura Q.M. Chow, Eric K. Rowinsky and Roger B. Cohen. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Molecular Cancer Therapeutics and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.